In this review:
SGLT-2 inhibitors and GLP-1 receptor agonists both lower cardiovascular-related mortality and non-fatal adverse cardiovascular events when added to other type 2 diabetes treatments, but the relative benefits of these two drug classes remain unclear. This publication summarises data from a systematic review and network meta-analysis that clarifies the differing benefits and risks for SGLT-2 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes. This review is sponsored by an educational grant from Boehringer Ingelheim and Eli Lilly. A free full-text PDF of the paper and its correction Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials BMJ 2021;372:m4573 is available here.
Please login below to download this issue (PDF)